Table 2 Correlations among IHC markers investigated in endometrial carcinomas
From: A functional role of LEFTY during progesterone therapy for endometrial carcinoma
LEFTY ρ (p) | pSmad2 ρ (p) | ERα ρ (p) | PR ρ (p) | Cyclin A2 ρ (p) | |
|---|---|---|---|---|---|
pSmad2 | 0.14 | * | * | * | * |
(0.15) | |||||
ERα | 0.37 | 0.12 | * | * | * |
(<0.0001) | (0.2) | ||||
PR | 0.3 | 0.16 | 0.61 | * | * |
(0.002) | (0.08) | (<0.0001) | |||
Cyclin A2 | −0.4 | −0.19 | −0.4 | −0.44 | * |
(<0.0001) | (0.05) | (<0.0001) | (<0.0001) | ||
Ki-67 | −0.37 | −0.24 | −0.25 | −0.22 | 0.75 |
(<0.0001) | (0.01) | (0.0009) | (0.18) | (<0.0001) |